| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers V > Headlines for Vanda Pharmaceuticals Inc. > News item |
Vanda completes schizophrenia, insomnia phase 3 trials ahead of schedule
By Elaine Rigoli
Tampa, Fla., Aug. 30 - Vanda Pharmaceuticals, Inc. said Wednesday that it completed enrollment in its iloperidone phase 3 clinical trial for the treatment of schizophrenia and its VEC-162 phase 3 clinical trial for the treatment of transient insomnia.
The company said it expects to report results for both trials in January.
If the iloperidone trial is successful, Vanda said it will file a New Drug Application with the Food and Drug Administration by the end of 2007.
The company said it will need to conduct additional phase 3 trials to receive FDA approval of VEC-162 for the treatment of insomnia.
Vanda is a biopharmaceutical company based in Rockville, Md.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.